![Gili Hart](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Gili Hart
Direktor/Vorstandsmitglied bei
ENLIVEX LTD.
Vermögen: 6 214 $ am 31.05.2026
Profil
Gili Hart currently works at SpliSense Ltd., as Chief Executive Officer from 2020, Quicklizard Ltd., as Independent Director from 2021, and Enlivex Therapeutics Ltd., as Independent Director from 2014.
Dr. Hart also formerly worked at OPKO Biologics Ltd., as Chief Executive Officer from 2004 to 2017, Mitoconix Bio Ltd., as Chief Executive Officer from 2017 to 2020, Enlivex Therapeutics Ltd., as Director, CollPlant Biotechnologies Ltd., as Independent Director from 2021 to 2023, OPKO Health, Inc., as Vice President-Biologics, and Prolor Biotech Ltd., as VP-Pre-Clinical & Clinical Pharmacology from 2009 to 2013.
Dr. Hart received her graduate degree and doctorate degree from Weizmann Institute of Science and undergraduate degree from Technion Institute.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ENLIVEX LTD. 0 % | 18.03.2026 | 7.672 ( 0 % ) | 6 214 $ | 31.05.2026 |
Aktive Positionen von Gili Hart
| Unternehmen | Position | Beginn |
|---|---|---|
| ENLIVEX LTD. | Direktor/Vorstandsmitglied | 01.01.2014 |
| QUICKLIZARD LTD | Direktor/Vorstandsmitglied | 21.02.2021 |
SpliSense Ltd.
 SpliSense Ltd. Pharmaceuticals: MajorHealth Technology Develops antisense therapeutics for genetic diseases | Vorstandsvorsitzender | 01.01.2020 |
Ehemalige bekannte Positionen von Gili Hart
| Unternehmen | Position | Ende |
|---|---|---|
| COLLPLANT BIOTECHNOLOGIES LTD. | Direktor/Vorstandsmitglied | 05.07.2023 |
Mitoconix Bio Ltd.
 Mitoconix Bio Ltd. BiotechnologyHealth Technology Develops novel therapeutics to improve mitochondrial health as a disease-modifying therapeutics for neurodegenerative diseases | Vorstandsvorsitzender | 01.01.2020 |
OPKO Biologics Ltd.
 OPKO Biologics Ltd. BiotechnologyHealth Technology Operates as a drug development company that develops bio-better long-acting therapeutic proteins | Vorstandsvorsitzender | 01.01.2017 |
Prolor Biotech Ltd.
 Prolor Biotech Ltd. BiotechnologyHealth Technology Develops proprietary versions of already-approved therapeutic proteins | Corporate Officer/Principal | 01.01.2013 |
Enlivex Therapeutics Ltd. /Old/
 Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions | Direktor/Vorstandsmitglied | - |
Ausbildung von Gili Hart
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
21
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
OPKO Biologics Ltd.
OPKO Biologics Ltd. BiotechnologyHealth Technology Operates as a drug development company that develops bio-better long-acting therapeutic proteins | Health Technology |
Weizmann Institute of Science
 Weizmann Institute of Science Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OPKO Health, Inc.
 OPKO Health, Inc. Medical/Nursing ServicesHealth Services Engages in biopharmaceutical and diagnostics | Health Services |
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions | Health Technology |
CollPlant Biotechnologies Ltd.
 CollPlant Biotechnologies Ltd. Medical SpecialtiesHealth Technology Develops and commercializes medical devices | Health Technology |
Technion Institute
 Technion Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Quicklizard Ltd.
 Quicklizard Ltd. Packaged SoftwareTechnology Services Develops AI based pricing platform for e-Commerce and Omni channel retailers | Technology Services |
Prolor Biotech Ltd.
Prolor Biotech Ltd. BiotechnologyHealth Technology Develops proprietary versions of already-approved therapeutic proteins | Health Technology |
Mitoconix Bio Ltd.
Mitoconix Bio Ltd. BiotechnologyHealth Technology Develops novel therapeutics to improve mitochondrial health as a disease-modifying therapeutics for neurodegenerative diseases | Health Technology |
Enlivex Therapeutics Ltd.
 Enlivex Therapeutics Ltd. BiotechnologyHealth Technology Develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions | Health Technology |
SpliSense Ltd.
SpliSense Ltd. Pharmaceuticals: MajorHealth Technology Develops antisense therapeutics for genetic diseases | Health Technology |
